Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718221 | 0.88 | MCHR1 (0.38) | MRGPRX4 | |
| SCHEMBL2825825 | 0.83 | NPC1 (0.31) | RAB9AMEN1KMT2A | |
| SCHEMBL2720238 | 0.72 | PPARD (0.34) | MRGPRX4MEN1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL2719431 | 0.71 | RAB9A (0.35) | MRGPRX4RAB9ADRD2HRH3KCNH2 | |
| SCHEMBL17614876 | 0.71 | ESR2 (0.45) | RAB9AHRH3SIGMAR1MEN1KMT2A | |
| SCHEMBL11063160 | 0.69 | ESR2 (0.46) | RAB9AHRH3SIGMAR1MEN1KMT2A | |
| SCHEMBL2133033 | 0.68 | DRD2 (0.44) | MRGPRX4RAB9ADRD2HRH3KCNH2 | |
| SCHEMBL9586183 | 0.67 | NQO1 (0.61) | RAB9ADRD2HRH3KCNH2CYP3A4 | |
| SCHEMBL2719083 | 0.67 | RAB9A (0.41) | RAB9ADRD2HRH3KCNH2CYP3A4 | |
| SCHEMBL12990842 | 0.65 | ESR2 (0.53) | RAB9ADRD2HRH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1995245-B1 | METHOD FOR PRODUCING EPOXY COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-2133380-A1 | RESIN COMPOSITION | Sumitomo Chemical Company, Limited (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20090054669-A1 | Process For Producing Epoxy Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090018355-A1 | Process for Crystallizing an Epoxy Compound | SUMITOMO CHEMICAL COMPANY, LTD. | 2009-01-15 | — | — | US | disclosed |
| EP-1995245-A1 | METHOD FOR PRODUCING EPOXY COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-11-26 | — | — | EP | disclosed |
| EP-1995244-A1 | METHOD FOR CRYSTALLIZATION OF EPOXY COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018355-A1 | Process for Crystallizing an Epoxy Compound | PTGER1, NR5A1, TCP1 | MRGPRX4 1599/4885RAB9A 3113/4885L3MBTL1 4450/4885 |
| US-20090054669-A1 | Process For Producing Epoxy Compound | RER1, AR, CYP1A1 | MRGPRX4 1036/4885RAB9A 1772/4885L3MBTL1 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.